Louis Garguilo
ARTICLES BY LOUIS
-
11/16/2026
In Japan, a practicing medical doctor becoming an entrepreneur and the CEO of a biotech start-up is still relatively rare. Rarer is when Yusaku Katada, M.D., Ph.D., founded Restore Vision, and selected a U.S. CDMO to usher his program through development and manufacturing. That program is a visual-restoration, gene-therapy technology for inherited retinal disease ("IRD"). Regarding that U.S.-based CDMO selection, there’s an ironic twist to along with this interesting back story.
-
11/13/2026
The U.S. government may be relenting on WuXi AppTec. At the least, it’s walked a step backwards in its attempt to target the CDMO, reports Chief Editor Louis Garguilo. The Department of Defense (DoD) has removed WuXi AppTec from its list of Chinese military companies. Here's analysis of what happened, and what might happen next.
-
11/12/2026
Heather Walters of CRB spends her time thinking about effective business and industrial sustainability and resource conservation. Meanwhile, Chief Editor Louis Garguilo maintains a position near the bottom of the list of interested parties. It made for great conversation. Uncovered were the current realities of sustainability in manufacturing facilities, and the importance of two components: electrification and digital twins.
-
11/10/2026
A CDMO employs accomplished professionals, operates modern facilities, and still frustrates the heck out of you. Accumulated talent and capabilities are impressive, but closer examination reveals the problem lies between the lines of the CDMO’s work demarcations. Instead, you need your CDMO to operate as a constellation of unified skills. Chief Editor Louis Garguilo explores this "holistic pattern of work that forms an interconnected organization, and presents a clear picture of management and culture."
-
11/4/2026
Consultants tell Chief Editor Louis Garguilo that too often those who should know better – from executives to project managers – overestimate their ability to manage CMC activities.
That’s surprising, and suggests a fundamental - but detailed - refresher of the key positioning of CMC is in order as we approach yearend.
-
10/30/2026
A supply-chain reformer, book author, strategic advisor to drug sponsors of all sizes, investors, and policymakers, says, “The non-clinical supply chain as the foundation of reliable commercial supply receives too little attention from prospective clinical trial sponsors. We could be doing a heck of a lot better." A discussion between Hedley Rees and our Chief Editor, Louis Garguilo.
-
10/26/2026
The biopharmaceutical's “Valley of Death” is entered through a desert of dwindling funding. Chief Editor Louis Garguilo talks with two consultants on avoiding financial failure when outsourcing development and manufacturing. The many contributing factors for failure may have a common denominator: Project Management is an overlooked financial savior.
-
10/19/2026
Subpar customer service at CDMOs is no longer something sponsors tolerate; there’s enough competition where they can move on. The other side of the coin is how difficult sponsors sink to the bottom of CDMO priorities; providers also have options. Here's an analysis less about technical components of outsourcing, and more on mutual satisfactions from working together to fulfill contractual arrangements and missions.
-
10/13/2026
The FDA calls on your CDMO; inspectors are fortified by data in AI models, and appear practically clairvoyant. “It won’t be like the ‘old days,’” says David Grote of GrayMatters Partners, an organization that advises on quality systems and inspection readiness. The agency earlier rolled out Elsa, an AI-enable data architecture. Now its added an impressive HALO - Harmonized AI & Lifecycle Operations for Data.
-
10/8/2026
A number of patients report receiving half a pill in a blister pack of their prescribed medicine. The initial sponsor reaction is to place the problem at an external partner’s production or packaging line. But overall responsibility lies with the sponsor, and the true extent of the problem is hard to detect. Enter AI. Experienced pharma quality expert Damiano Dragone believes AI combined with professionals throughout the supply chain can join in a new “logic and creativity" to improve our industry on behalf of patients.